In vitro activity of daptomycin and comparator agents against Staphylococcus aureus isolates from intravenous drug users with right endocarditis.
There is an increasing need for alternative agents in endocarditis, especially with the increasing incidence of vancomycin-intermediate Staphylococcus aureus (VISA). We evaluated the in vitro activity of daptomycin and several comparator agents against 33 non-duplicate clinical Staphylococcus aureus isolates from intravenous drug users with right endocarditis. Wider microdilution panels were used for all the comparator agents and daptomycin. Daptomycin was also tested using E-test strips. E-test strips were used to confirm the vancomycin MICs. Methicillin-resistant Staphylococcus aureus (MRSA isolates with vancomycin MICs ≥ 2 g/mL were screened using the E-test GRD. In all, 30 isolates were methicillin-susceptible (MSSA) and 3 MRSA. The three MRSA isolates exhibited a false vancomycin MIC >2 g/mL determined by Wider microdilution panels. They were screened using the E-test GRD and they were GRD negative. Their final MIC was 2 g/mL. Three MSSA and three MRSA isolates had a vancomycin MIC of 2 g/mL. Four MSSA isolates had a vancomycin MIC of 1.5 g/mL, daptomycin MIC90 0.25 g/mL, linezolid MIC90 2 g/mL. As regards daptomycin, wider microdilution panels and E-test strips yielded the same results. Our findings suggest that daptomycin and linezolid are a viable alternative for treating right endocarditis and bacteraemia caused by MSSA, MRSA and hVISA.
Sanchez-Porto
Antonio
A
Department of Microbiology, Hospital of La Línea, Cádiz, Spain.
Casanova-Roman
Manuel
M
Casas-Ciria
Javier
J
Santaella
Maria Jose
MJ
Sanchez-Morenilla
Immaculada
I
Eiros-Bouza
Jose Maria
JM
D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016470:Bacteremia / Q000150:complications / Q000382:microbiology; D002462:Cell Membrane / Q000187:drug effects; D015169:Colony Count, Microbial; D017576:Daptomycin / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D024901:Drug Resistance, Multiple, Bacterial; D004697:Endocarditis, Bacterial / Q000209:etiology / Q000382:microbiology*; D006801:Humans; D066298:In Vitro Techniques; D000069349:Linezolid; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology; D011934:Reagent Strips; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D015819:Substance Abuse, Intravenous / Q000150:complications*; D020713:Vancomycin Resistance
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D011934:Reagent Strips; D000069349:Linezolid; D017576:Daptomycin